Search
for
Sort by
Research 991–1000 of 1000+
- Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Safety and Clinical Efficacy of KūlarisTM, an Herbal Supplement for Mild to Severe Acne Vulgaris – A 12-Week Randomized, Double Blind, Placebo-Controlled Study
- A Novel Approach Against Male Pattern Hair Loss With Topical Dimethylglycine Sodium Salt (DMG‐Na) and Caffeine: Efficacy of a 24‐Week, Double‐Blind, Randomized, Placebo‐Controlled Trial
- Hair density response to photobiomodulation in canine alopecia X is measured reliably with an ordinal scale: a randomized, controlled, double-blind study
- Evaluation of Efficacy of Water-Soluble Fraction of Rhus semialata Gall Extract and Penta-O-Galloyl-β-D-Glucose on Mitigation of Hair Loss: An In Vitro and Randomized Double-Blind Placebo-Controlled Clinical Study
- Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
- Commentary on Clinical Safety and Efficacy of Dual Wavelength Low Level Light Therapy in Androgenetic Alopecia; A Double-Blind Randomized Controlled Study
- Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
- 51252 Oral supplementation with L-Cystine, Serenoa repens, Pumpkin seed oil and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A double-blind, placebo-controlled, randomized clinical study